Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study [0.03%]
载药微球TACE治疗肝癌的研究：idarubicin与epirubicin的疗效对比——一项真实世界回顾性研究
Chenghao Zhao,Huzheng Yan,Zhanwang Xiang et al.
Chenghao Zhao et al.
The purpose of this study was to compare the efficacy and safety of idarubicin-loaded drug-eluting beads-transarterial chemoembolization (IDA-TACE) and epirubicin-loaded drug-eluting beads-TACE (EPI-TACE) in treating hepatocellular carcinom...
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma [0.03%]
zanubrutinib与orelabrutinib治疗复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤或复发/难治性套细胞淋巴瘤疗效的间接比较研究
Yuqin Song,Keshu Zhou,Shenmiao Yang et al.
Yuqin Song et al.
We conducted two indirect comparisons to estimate the efficacy of zanubrutinib versus orelabrutinib in Chinese patients with relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or R/R mantle cell l...
Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates [0.03%]
tepotinib抑制剂对CYP3A4和P-糖蛋白底物药代动力学影响的潜力评估
Özkan Yalkinoglu,Andreas Becker,Axel Krebs-Brown et al.
Özkan Yalkinoglu et al.
Tepotinib is a highly selective, potent, mesenchymal-epithelial transition factor (MET) inhibitor, approved for the treatment of non-small cell lung cancer harboring MET exon 14 skipping alterations. The aims of this work were to investigat...
The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells [0.03%]
胰腺癌细胞中p53活化剂PRIMA-1MET与氟尿嘧啶协同诱导凋亡
Ibtehal Mohammed,Ali Haider Alhammer,Inam Sameh Arif
Ibtehal Mohammed
Pancreatic cancer (PC) is one of the deadliest malignancies; p53 is mutated in approximately 75% of PC patients. Hence, the protein derived from mutant/wild-type TP53 may represent a therapeutic target. Interestingly, a p53 reactivator (PRI...
Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study [0.03%]
免疫治疗联合化疗用于局部晚期胃癌新辅助治疗的安全性和有效性：一项回顾性队列研究
Xue Wang,Jinxiang Huang,He Huang et al.
Xue Wang et al.
Background: The combined use of programmed death receptor-1 (PD-1) inhibitors and chemotherapy has reshaped the treatment landscape of advanced or metastatic gastric cancer (GC). This study aimed to assess the efficacy an...
Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma [0.03%]
西塔拉 vinib 是一种潜在的 EGFR 抑制剂并可在胶质母细胞瘤中引发新的死亡表型
Hanwen Lu,Bingchang Zhang,Yuanyuan Xie et al.
Hanwen Lu et al.
Glioblastoma (GBM) is a highly lethal neurological tumor that presents significant challenge for clinicians due to its heterogeneity and high mortality rate. Despite extensive research, there is currently no effective drug treatment availab...
POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma [0.03%]
POTEE突变可能是免疫检查点抑制剂治疗肺腺癌的预测生物标志物
Yongzhao Li,Qidong Yang,Yaqin Liu et al.
Yongzhao Li et al.
Precise selection of patients who could benefit from immune checkpoint inhibitors (ICIs) is an important challenge for immunotherapy in lung cancer. POTEE (POTE Ankyrin Domain Family Member E) is a member of one primate-specific gene family...
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma [0.03%]
LY3022855与BRAF/MEK抑制剂联合治疗黑色素瘤I/II期临床试验
Elizabeth I Buchbinder,Anita Giobbie-Hurder,Rizwan Haq et al.
Elizabeth I Buchbinder et al.
BRAF/MEK targeted therapies and immune checkpoint inhibition have dramatically improved disease control and survival of patients with advanced melanoma. However, most patients do not have durable benefit from either of these therapies. BRAF...
Correction to: The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma [0.03%]
纠正：肾细胞癌中动力蛋白马达蛋白KIF4A作为潜在治疗靶点
Guihong Liu,Yachun Lu,Liantao Li et al.
Guihong Liu et al.
Published Erratum
Investigational new drugs. 2023 Aug;41(4):627-628. DOI:10.1007/s10637-023-01361-8 2023
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells [0.03%]
抗癌药物COTI-2通过降解MYC基因抑制乳腺癌细胞的生长和发展
Minhong Tang,John Crown,Michael J Duffy
Minhong Tang
TP53 (p53) and MYC are amongst the most frequently altered genes in cancer. Both are thus attractive targets for new anticancer therapies. Historically, however, both genes have proved challenging to target and currently there is no approve...